Heart Health Co. Sues Rival Over Genetic Test Patent

Law360, Washington (December 9, 2013, 8:04 PM EST) -- Heart health management company Boston Heart Diagnostics Corp. launched a suit in Massachusetts federal court Monday alleging a laboratory testing company's genetic testing for statin-induced myopathy risk violates Boston Heart's licensed patent for the same testing.

Boston Heart informed Health Diagnostic Laboratory Inc. that its genetic testing infringed U.S. Patent No. 8,455,194, which covers diagnostic methods for identifying individuals who are at risk of severe muscle aches and pains, or myopathy, caused by statin drugs used to reduce cholesterol levels.

But Boston Heart claims HDL has...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.